Clinical Trials Logo

Fuchs' Endothelial Dystrophy clinical trials

View clinical trials related to Fuchs' Endothelial Dystrophy.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04527523 Terminated - Clinical trials for Cystoid Macular Edema

Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only

Start date: November 21, 2020
Phase:
Study type: Observational

This study aims to evaluate and compare incidence of post-operative cystoid macular edema (CME) after Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet's Stripping Automated endothelial Keratoplasty (DSEK) and Descemet Stripping Only (DSO).

NCT ID: NCT03971357 Terminated - Clinical trials for Fuchs' Endothelial Dystrophy

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Start date: July 22, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

NCT ID: NCT01586234 Terminated - Clinical trials for Fuchs' Endothelial Dystrophy

OCT-guided DSAEK Graft Shaping and Smoothing

DSAEK
Start date: January 2012
Phase: N/A
Study type: Interventional

The primary goal of this study is to determine if excimer laser smoothing of the cornea before Descemet's stripping automated endothelial keratoplasty (DSAEK)improves postoperative Best Spectacle Corrected Visual Acuity (BSCVA).

NCT ID: NCT01361282 Terminated - Cataract Clinical Trials

Using the Optovue OCT to Select IOL Power

Start date: November 9, 2010
Phase: N/A
Study type: Observational

Many patients with endothelial dysfunction also present with cataracts. It is therefore common practice to perform cataract extraction and intraocular lens (IOL) implantation during the same operation and immediately prior to Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK), in order to minimize trips to the operating room and the associated risks of ocular surgery. However, the unique posterior corneal anatomy of the DSAEK recipient makes it difficult to predict pre-operatively the proper power of IOL to place, and some patients end up with a mismatched lens that requires spectacle correction. The current gold standard for IOL power calculation (A-Scan optical biometry) takes measurements of the anterior surface of the cornea and makes assumptions about the posterior surface that are violated by the unique hourglass shape of the donor DSAEK graft. New optical coherence tomography (OCT) technology provides us with the ability to measure curvature in both the anterior and posterior aspects of the cornea in order to generate an IOL calculation that has the potential to give more accurate results for our DSAEK patients. The investigators will be using the Optovue to perform corneal power analysis on patients who have already received DSAEK and cataract surgery, in order to compare the post-op Optovue power calculations to the pre-operative power calculations provided by the A-Scan. If the OCT is shown to provide accurate IOL power calculations, then some patients might be better served by a two-stage procedure where DSAEK is performed and then followed six months later by cataract surgery using the OCT to calculate IOL power.